Bayhill Therapeutics teams up with Genentech to develop new approach to treat Type 1 diabetes
SAN MATEO, Calif. Bayhill Therapeutics announced its exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech.
BHT-3021 is Bayhill’s DNA-based antigen immunotherapy currently in a phase one/ two clinical trial with Type 2 diabetic patients.
According to Mark W. Schwartz, PhD, CEO and president of Bayhill, “BHT-3021 represents a truly novel approach to treating Type 1 diabetes. We believe this collaboration with Genentech reflects the significant potential of our approach to antigen specific tolerance, and will allow us to accelerate and expand the development of BHT-3021, while continuing to develop additional products from our BHT-DNA platform.”
Under the recent agreement, Bayhill will complete the continuing phase one/ two clinical trial, while Genentech will be responsible for future research, development, manufacturing and commercialization efforts.
“The ultimate goal for treatment of autoimmune disease is antigen specific therapy,” said Lawrence Steinman M.D., founder, director and chairman of Bayhill’s scientific advisory board.
Aurora Health Care to honor cancer survivors
MILWAUKEE With more people diagnosed with cancer every year but more of them surviving, a nonprofit healthcare system in eastern Wisconsin plans to honor cancer survivors.
Aurora Health Care, which runs the Aurora Pharmacy chain as well as a network of hospitals and clinics, announced Tuesday that it would mark National Cancer Survivors Day on Saturday with several events in three Wisconsin cities.
“There has been great progress in cancer prevention, early detection and treatment that has resulted in ever-increasing numbers of survivors,” Aurora Health Care VP cancer services Joseph Mirro said. “Now that more patients are being cured of their cancer and living longer, there’s a growing number of survivors with unique needs.”
Events will include a walk and run for cancer in Milwaukee, a gathering in Sheboygan and booths offering cancer screenings and information in Oshkosh.
FDA gives tentative approval to generic breast cancer treatment
ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to a generic drug for treating breast cancer.
The drug, Roxane Labs’ letrozole tablets in the 2.5 mg strength, is a generic version of Novartis’ Femara.
Femara had global sales of $1.13 billion in 2008, according to Novartis financial data. Novartis’ patent on the drug will expire in 2011, according to the FDA’s Orange Book.